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Summary
It is known that several of the most severe complications
of autosomal-dominant polycystic kidney disease, such
as intracranial aneurysms, cluster in families. There have
been no studies reported to date, however, that have
attempted to correlate severely affected pedigrees with
a particular genotype. Until recently, in fact, mutation
detection for most of the PKD1 gene was virtually im-
possible because of the presence of several highly ho-
mologous loci also located on chromosome 16. In this
report we describe a cluster of 4 bp in exon 15 that are
unique to PKD1. Forward and reverse PKD1-specific
primers were designed in this location to amplify regions
of the gene from exons 11–21 by use of long-range PCR.
The two templates described were used to analyze 35
pedigrees selected for study because they included in-
dividuals with either intracranial aneurysms and/or
very-early-onset disease. We identified eight novel trun-
cating mutations, two missense mutations not found in
a panel of controls, and several informative polymor-
phisms. Many of the polymorphisms were also present
in the homologous loci, supporting the idea that they
may serve as a reservoir for genetic variability in the
PKD1 gene. Surprisingly, we found that three indepen-
dently ascertained pedigrees had an identical 2-bp de-
letion in exon 15. This raises the possibility that partic-
ular genotypes may be associated with more-severe
disease.
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Introduction
PKD1, the gene mutated in the most common form of
autosomal-dominant polycystic kidney disease (ADPKD
[MIM 173900]) is predicted to encode a novel 460-kD
membrane protein of unknown function (American
PKD1 Consortium 1995; Hughes et al. 1995; Interna-
tional Polycystic Kidney Disease Consortium 1995). Its
gene product has a number of domains found in other
proteins that function as receptors for either extracel-
lular-matrix or other cell-surface proteins, prompting
speculation that PKD1 plays a similar role in renal and
biliary epithelial cells. No functional studies have yet
been reported that confirm these predictions, however.
One strategy commonly used to gain insights into the
properties of a disease-associated gene is to define the
pattern of mutations present in affected individuals. This
approach can identify functionally important domains
that can be targeted for experimental investigation. An-
other advantage of this strategy is that correlation of
genotypes with detailed clinical evaluations may provide
clinically useful information. In the case of ADPKD, it
has been previously shown that the most severe com-
plications of the disease, such as intracranial aneurysms,
aortic dissections, and early-onset disease, often cluster
in families (Chapman et al. 1992; Fick et al. 1993; Zerres
et al. 1993). It is not known, however, whether the fa-
milial clustering is the result of particular types of mu-
tations that are associated with specific phenotypic fea-
tures or of the effects of other genetic factors encoded
by distinct loci. None of the published PKD1mutations,
except for the small subset that also disrupts the adjacent
tuberous sclerosis 2 gene (TSC2), appear to be associated
with a particular phenotype (Brook-Carter et al. 1994).
It should be noted, however, that none of the studies
have been performed on a large panel of patients who
suffer from the most severe forms of disease and that
relatively few mutations have been described (summa-
rized in the Human Gene Mutation Database).
A number of features of the PKD1 gene’s structure
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Figure 1 PKD1 gene, which contains 46 exons and is bisected
by a polypyrimidine tract of ∼2.5 kb (diagonally striped box). The
replicated portion of the gene begins with exon 1 and is thought
to end in exon 34 (stippled box [European Polycystic Kidney Dis-
ease Consortium 1994]). Two locus-specific PCR products, 5′ MR
(black) and 5′ LR (vertically striped) were used for mutation de-
tection. The approximate position of the two templates, along with
the primers used to amplify them, is indicated.
have greatly hindered efforts to complete genotype/phe-
notype analyses. PKD1 is encoded by 46 exons that yield
a coding sequence 113 kb (Hughes et al. 1995 [GenBank
accession numbers L33234 and L39891 for PKD1
cDNA and genomic sequence, respectively]). Approxi-
mately 70% of the gene’s length (exons 1–34; fig. 1) is
replicated elsewhere on chromosome 16, in multiple
highly homologous copies that are also transcribed (Ger-
mino et al. 1992; European Polycystic Kidney Disease
Consortium 1994). The sequence identity in the repli-
cated segments is 195% and includes both exonic and
intronic sequences. Thus, mutation detection in the rep-
licated region of the gene depends on the identification
of locus-specific primers that can selectively amplify
PKD1 but not its homologues.
Both our group and others have previously used a
unique sequence in the 3′ portion of PKD1 to design
anchor primers for long-range amplification of exons
23–34 from both cDNA and genomic DNA (Peral et al.
1997; Roelfsema et al. 1997; Watnick et al. 1997). These
gene-specific templates have been successfully employed
for mutation analysis by use of a number of techniques,
including heteroduplex analysis and single-strand con-
formation analysis (SSCA). Amplification of longer tem-
plates from genomic DNA has been difficult because of
the presence of a long, 2.5-kb polypyrimidine tract in
intron 21 and a shorter element in intron 22 (Van Raay
et al. 1996). The high degree of sequence identity be-
tween PKD1 and its homologues has made it difficult
to design additional PKD1-specific primers that could
be used to anchor amplification of the 5′ end of the gene
(Watnick et al. 1998a). Another complicating factor is
the additional observation that not all of the homologues
(at least three) differ from PKD1 in exactly the same
location.
In this study we report a cluster of 4 bp in exon 15
that are unique to PKD1. Both forward and reverse
primers were designed to exploit these differences and
were used to amplify PKD1-specific products of ∼3.5 (5′
middle range [MR]) and ∼6.0 kb (5′ longer range [LR]).
Together, these templates contain ∼5.5 kb of coding se-
quence. A series of control reactions was employed to
confirm the specificity of 5′ MR and 5′ LR and to dem-
onstrate that they can serve as templates for nested am-
plification of gene-specific fragments if appropriately di-
luted. We used this approach to evaluate genomic DNA
samples from 35 pedigrees with individuals having
ADPKD along with either early-onset disease and/or in-
tracranial aneurysms. We identified eight pathogenic se-
quence changes, several variants associated with disease
and not found in normal individuals, and a variety of
useful polymorphisms. Three independently ascertained
and unrelated pedigrees were found to share an identical
pathogenic mutation.
Subjects and Methods
Patient Recruitment
The University of Colorado Polycystic Kidney Re-
search Study has 806 affected individuals who have par-
ticipated in the ongoing natural-history study of
ADPKD. All patients who participated in the study un-
derwent a formalized history and physical examination
and complete abdominal ultrasonography, as described
elsewhere (Gabow et al. 1989). A subset of patients also
participated in the study of intracranial aneurysms in
ADPKD, as described elsewhere (Chapman et al. 1992).
An additional set of patients was recruited from dialysis
centers and nephrology clinics in Baltimore. All patients
who participated in the studies had blood obtained for
genetic analysis. Informed consent was obtained from
all patients, in accordance with institutional guidelines
at University of Colorado and Johns Hopkins University.
For this study, DNA samples were utilized from patients
who were diagnosed during the 1st year of life (very
early onset) and from individuals who had a documented
intracranial aneurysm, whether ruptured or unruptured
(Chapman et al. 1992, Fick et al. 1993).
Long-Range PCR
DNA was isolated from whole blood by use of a PE
Biosystems 340A nucleic-acid–extractionmachine or the
PureGene DNA-extraction kit (Gentra). Three hundred
nanograms of genomic DNA was then used as template
for amplification of a ∼3.5-kb product (5′ MR), by use
of primers F26 (5′-AGCGCAACTACTTGGAGGCCC-
3′, genomic position 30606–30626) and R2LR (5′-
GCAGGGTGAGCAGGTGGGGCCATCCTAC-3′, ge-
nomic position 33957–33984). 5′ LRwas amplified from
400 ng of genomic template by use of primers F11 (5′-
TGCCCCTGGGAGACCAACGATAC-3′, genomic po-
sition 24911–24933) and R27 (5′-GTCAACGTGGG-
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CCTCCAAGT-3′, genomic position 30615–30634). For
the cell lines 145.19 and N23HA, 400 ng of genomic
DNA, prepared by use of the Puregene kit, was always
used as template. PCR was performed as follows for 5′
MR: denaturation at 95C for 3 min, 35 cycles at 95C
for 20 s and 70C for 4 min and 30 s, and a final ex-
tension at 72C for 10 min. The total PCR volume was
50 ml, with 4 units of rTth DNA polymerase (XL; PE
Biosystems) and a final MgOAC2 concentration of 1.1
mM. For 5′ LR, the following PCR conditions were em-
ployed: denaturation at 95C for 3 min and 15 s, 35
cycles at 95C for 20 s and 68C for 7 min, and a final
extension at 72C for 10 min. The PCR-reaction mix
was the same as that described for 5′ MR, except that
the final MgOAC concentration was 1.0 mM. A hot-
start protocol as recommended by the manufacturer was
used for the first cycle of amplification. Products of the
long-range PCR reaction were run on a 1% agarose gel
to confirm that the reaction was successful before the
next step was undertaken. The specificity of long-range
products was evaluated by testing for the presence of a
PCR product containing exon 32. The primers and con-
ditions for this PCR reaction have been published else-
where (Watnick et al. 1997).
SSCA Analysis
The long-range products 5′ MR and 5′ LRwere diluted
serially to 1 : 104, and 2 ml of diluted template was used
as template for all subsequent PCR reactions. Intron-
based primers were designed for each exon with the
exception of exon 15, which required amplification in
18 separate overlapping fragments. Only a portion of
exon 11 is contained in 5′ LR. In total, 25 different
primer pairs were designed. The sequences of these prim-
ers and the PCR-reaction conditions are summarized in
table 1. The total PCR volume was 20 ml, with 2 units
of Taq DNA polymerase (Boehringer Mannheim), 0.2
ml dCTP, and a final MgCl2 concentration of 1.5 mM.
SSCA analysis was performed by use of 8% poly-
acrylamide gels with 5% glycerol added. The radiola-
beled PCR products were diluted with loading buffer,
were denatured by heating at 95C for 5 min, and then
were placed on ice prior to being loaded and run on the
gel at room temperature. Gels were run at 400 V over-
night, dried, and placed on X-Omat XAR film (Kodak)
at room temperature. PCR products with variants were
reamplified from the diluted template and were purified
from an agarose gel slice by means of Qiajex and the
manufacturer’s protocol (Qiagen) or, alternatively, di-
rectly with Centricon-100 columns (Amicon). When
possible, mutant SSCP bands were also excised from the
agarose gel, and the DNA was eluted and used for PCR
amplification and then for sequencing. In the case of
certain sequence variants containing insertions or dele-
tions, the PCR product was cloned into pCRII (TAClon-
ing Kit; Invitrogen) prior to being sequenced. PCR prod-
ucts and clones were sequenced with 32P cycle sequencing
by use of the Thermosequenase kit (Amersham). When
possible, sequence differences were confirmed by restric-
tion digestion of PCR products by use of restriction en-
zymes whose recognition sites were altered by the se-
quence change in question. In several instances, the
change did not alter a restriction site, so mismatch oli-
gonucleotides were designed that introduce a new re-
striction site when combined with the point mutation in
question (Shoffner 1998). The primers were designed to
create a restriction site when the alteration in question
was present. For the G5689A mutation in UC109 (table
2), the primers 15-6StopF (5′-CGAGCCATTTACCA-
CCCATAGCTTCC-3′) and 15-6StopR (5′-ATTGGT-
GCCCGTGGCCAGCAGCGC-3′) were used with the
enzyme Eco47III. For the polymorphism in exon 18, the
primer 18PolyF (5′-GCTCTTGCCGCCTCTTCCCA-3′)
was used in combination with 18R (table 1) and the
enzyme NsiI. Pathogenic mutations were confirmed in
family members, when possible, by SSCA or by restric-
tion digest.
Results
Locus-Specific Templates
In the process of assembly of a cDNA contig, a series
of clones was identified that, in 4 bp clustered in a short
stretch of exon 15 (fig. 2), differed from PKD1. Because
more than one clone contained these sequence differ-
ences, we hypothesized that these clones were likely to
be derived from the homologous loci and not from
PKD1. A subsequent search of the GenBank database
identified the sequence of a bacterial artificial chromo-
some (BAC) that maps to 16p13.1 and contains two
homologous copies of PKD1 (GenBank accession num-
ber AC002039). Although one copy lacked most of exon
15, the other copy contained the same 4-bp substitutions
as did the cDNA clones presumed to have originated
from the homologous loci. To take advantage of this
PKD1-specific sequence, forward (F26) and reverse
(R27) primers were designed to incorporate all 4-bpmis-
matches with one at the 3′ terminus, to maximize spec-
ificity (fig. 2). Both primers work well for long-range
PCR and can be used to amplify products of ∼3.5 (5′
MR) and ∼6.0 kb (5′ LR) from genomic DNA (Watnick
et al. 1998b). These templates span part of exons 11–21
and include ∼5.5 kb of coding sequence (fig. 1 and Sub-
jects and Methods). The two templates overlap at the
site of the PKD1-specific primer.
To prove that the primers F26 and R27 are PKD1
specific, we used two cell lines that have been described
elsewhere. In brief, N23HA is a rodent-human somatic-
Table 1
Primers Used for Mutation Detection
Exon Primers
Fragment
Size
(bp)
Annealing
Temperature
(C)
5′ LR:
11 F11: 5′-TGCCCCTGGGAGACCAACGATAC-3′ 303 67
11R1: 5′-GGCTGCTGCCCTCACTGGGAAG-3′
12 12F: 5′-GAGGCGACAGGCTAAGGG-3′ 286 64
12R: 5′-CATGAAGCAGAGCAGAAGGC-3′
13 13F: 5′-TGGAGGGAGGGACGCCAATC-3′ 308 67
13R: 5′-GAGGCTGGGGCTGGGACAAG-3′
14 14F: 5′-CCCGGTTCACTCACTGCG-3′ 220 64
14R: 5′-CCGTGCTCAGAGCCTGAAAG-3′
15 15F16: 5′-CGGGTGGGGAGCAGGTGG-3′ 280 67
15R16: 5′-GCTCTGGGTCAGGACAGGGGA-3′
15F15: 5′-CGCCTGGGGGTGTTCTTT-3′ 270 64
15R15: 5′-ACGTGATGTTGTCGCCCG-3′
15F14: 5′-GCCCCCGTGGTGGTCAGC-3′ 250 67
15R14: 5′-CAGGCTGCGTGGGGATGC-3′
15F13: 5′-CTGGAGGTGCTGCGCGTT-3′ 256 67
15R13: 5′-CTGGCTCCACGCAGATGC-3′
15F12: 5′-CGTGAACAGGGCGCATTA-3′ 270 65
15R12: 5′-GCAGCAGAGATGTTGTTGGAC-3′
15F11: 5′-CCAGGCTCCTATCTTGTGACA-3′ 259 60
15R11: 5′-TGAAGTCACCTGTGCTGTTGT-3′
15F10: 5’-CTACCTGTGGGATCTGGGG-3’ 217 67
15R10: 5′-TGCTGAAGCTCACGCTCC-3′
15F9: 5′-GGGCTCGTCGTCAATGCAAG-3′ 267 67
15R9: 5′-CACCACCTGCAGCCCCTCTA-3′
15F8: 5′-CCGCCCAGGACAGCATCTTC-3′ 261 64
15R8: 5′-CGCTGCCCAGCATGTTGG-3′
15F7: 5′-CGGCAAAGGCTTCTCGCTC-3′ 288 64
15R7: 5′-CCGGGTGTGGGGAAGCTATG-3′
15F6: 5′-CGAGCCATTTACCACCCATAG-3′ 231 65
15R6: 5′-GCCCAGCACCAGCTCACAT-3′
15F5: 5′-CCACGGGCACCAATGTGAG-3′ 251 64
15R5: 5′-GGCAGCCAGCAGGATCTGAA-3′
15F4: 5′-CAGCAGCAAGGTGGTGGC-3′ 333 67
15R4: 5′-GCGTAGGCGACCCGAGAG-3′
15F3: 5′-ACGGGCACTGAGAGGAACTTC-3′ 206 64
15R3: 5′-ACCAGCGTGCGGTTCTCACT-3′
15F2: 5′-GCCGCGACGTCACCTACAC-3′ 265 67
15R2: 5′-TCGGCCCTGGGCTCATCT-3′
15F1: 5′-GTCGCCAGGGCAGGACACAG-3′ 228 68
R27: 5′-AGGTCAACGTGGGCCTCCAA-3′
5′ MR:
15 15F1-1: 5′-ACTTGGAGGCCCACGTTGACC-3′ 276 69
15R1-1: 5′-TGATGGGCACCAGGCGCTC-3′
15F1-2: 5′-CATCCAGGCCAATGTGACGGT-3′ 266 64
15R1-2: 5′-CCTGGTGGCAAGCTGGGTGTT-3′
16 16F: 5′-TAAAACTGGATGGGGCTCTC-3′ 294 56
16R: 5′-GGCCTCCACCAGCACTAA-3′
17 17F: 5′-GGGTCCCCCAGTCCTTCCAG-3′ 244 67
17R: 5′-TCCCCAGCCCGCCCACA-3′
18 18F: 5′-GCCCCCTCACCACCCCTTCT-3′ 342 67
18R: 5′-TCCCGCTGCTCCCCCCAC-3′
19 19F: 5′-GATGCCGTGGGGACCGTC-3′ 285 67
19R: 5′-GTGAGCAGGTGGCAGTCTCG-3′
20 20F: 5′-CCACCCCCTCTGCTCGTAGGT-3′ 232 64
20R: 5′-GGTCCCAAGCACGCATGCA-3′
21 21F: 5′-TGCCGGCCTCCTGCGCTGCTGA-3′ 232 67
TWR2: 5′-GTAGGATGGCCCCACCTGCT-
CACCCTGC-3′
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Figure 2 Cluster of 4 bp unique to PKD1. An alignment of
exon 15 sequence between PKD1 (accession number L33243) and
one of the homologous loci is shown. The second homologue pres-
ent in a BAC that maps to 16p13.11 (accession number AC002039)
lacks most of exon 15, including this region. The 4 bp that differ
between the two sequences are boxed and shaded. Forward (F26)
and reverse (R27) PKD1 primers were designed to include all four
mismatches, including one at the 3′ end of each primer. The lo-
cation of each primer is indicated by an arrow.
Table 2
Mutations Identified in a Panel of 35 Patients with Aneurysms and/or VEO Disease
Pedigree Phenotype Mutation Location Effect
UC062 VEO C32, 328G Intron 16/exon 17 Splice site disrupted
JHU471 VEO  Aneurysm 7397 ins 11 Exon 17 Frameshift
JHU295 Aneurysm 3220 del 4 Exon 13 Frameshift
UC591 VEO  Aneurysm 5224 del 2 Exon 15 Frameshift
UC138 Aneurysm 5224 del 2 Exon 15 Frameshift
UC1334 VEO 5224 del 2 Exon 15 Frameshift
UC125 Aneurysm 5782 del 1 Exon 15 Frameshift
UC834 VEO 3804 del 7 Exon 15 Frameshift
UC109 VEO G5689A Exon 15 F1825X
UC362 Aneurysm 6024 ins 1 Exon 15 Frameshift
cell hybrid that contains only the homologous loci,
whereas 145.19 is a radiation hybrid that contains only
PKD1 (Germino et al. 1990; Ceccherini et al. 1992;
European Polycystic Kidney Disease consortium 1994).
As shown in figure 3, 5′ MR and 5′ LR can be amplified
from the DNA of 145.19 but not from that of N23HA.
The DNA of N23HA does, however, support the am-
plification of similar-sized PCR products when appro-
priate primers are used (data not shown). 5′ MR and 5′
LR can be used for mutation analysis of exons 11–21
by use of techniques similar to those described for exons
23–34 (Watnick et al. 1997); that is, the templates can
be used for nested amplification once they have been
adequately diluted. A dilution 104 is required to re-
move contamination of total genomic DNA used in the
initial amplification reaction (fig. 4).
Probable Pathogenic Mutations
To show that this technique could be used to identify
sequence variants, we amplified 5′ MR and 5′ LR from
genomic DNA isolated from members of 35 pedigrees
selected because they had individuals with either very-
early-onset disease (VEO), aneurysms, or both. Criteria
for VEO disease have been described elsewhere (Fick et
al. 1993). Intron-based primers were designed for SSCA
screening of exons 11–21 (table 1). Exon 15 is ∼3.5 kb
in length and was therefore amplified in 18 overlapping
fragments.
Using SSCA, we identified eight distinct pathogenic
mutations among 10 families in exons 11–21, for a de-
tection rate of ∼28.5% (table 2). Seven mutations in-
volved insertions, deletions, or nonsense changes pre-
dicted to result in truncated proteins lacking the recepter
for egg jelly (REJ) domain, transmembrane spanning
regions, and the PKD1 C-terminus. For 6 of the 10 ped-
igrees, there was more than one family member available
for analysis, and the mutation could be shown to seg-
regate with the disease phenotype. One family (UC062)
had a CrG transversion at the 3 position of the exon
17 splice-acceptor site. Although, since a cytosine is con-
served in this position ∼65% of the time, this alteration
has a high likelihood of altering the splicing of this exon,
we were unable to obtain an RNA sample to demon-
strate this effect. The mutation was shared by three af-
fected family members and was not seen in 100 normal
chromosomes.
Several families were notable for variability in disease
presentation. One example is demonstrated in figure 5.
The proband, II-1, of pedigree JHU471 was found to
have chronic renal insufficiency in her 50s but was not
on dialysis at the time of submission of this article (age
∼54 years). Several family members with ADPKD, how-
ever, were more severely affected. She had a brother (II-
3) who died at age 31 years of a ruptured cerebral an-
eurysm and a niece (III-1) in whom an asymptomatic
intracranial aneurysm was detected that required sur-
gical intervention. Two additional family members (II-
4 and III-2) died shortly after birth, as a consequence
of VEO disease. The proband was found to have in exon
17 an aberrant SSCA band, which was sequenced and
found to contain an 11-bp insertion (fig. 5). Sequence
analysis revealed that the insertion contained a local 10-
bp duplication, with an additional base pair, a thymi-
dine, added at the beginning of the duplicated sequence.
This change was also found in III-1 and II-2. The latter
individual is not on dialysis at the age of ∼50 years.
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Figure 3 5′ MR (A) and 5′ LR (B), which are PKD1 specific.
Each template can be amplified from the genomic DNA of an in-
dividual (lane 1) and 145.19 (lane 2) but not from the cell line
N23HA (lane 3), which contains only the homologous loci. “M”
denotes the 1-kb ladder. The “extra” band seen in lane 1 is an
artifact of overloading. Hybridization studies of higher-resolution
gels, using an internal fragment, have shown that only a single
product is amplified with this primer pair.
Figure 4 Diluted long-range templates used for amplification
of gene-specific fragments. For both 5′ MR (right panel) and 5′ LR
(left panel), dilutions !103 are not sufficient to remove genomic
contamination that is present from the initial PCR reaction, since
products outside the template region (exon 32 in this figure) can
still be amplified. “M” denotes the 1-kb ladder.
Three pedigrees, UC138, UC1334, and UC591, were
discovered to have an identical 2-bp deletion in exon 15
(table 2 and fig. 6). Family UC138, from the University
of Colorado database, was selected for analysis because
it contained an individual with a cerebral aneurysm. This
individual (III-1; fig. 6) was the only member of the
family for whom a DNA sample was available. Family
UC1334 was evaluated because of a child (III-1) with
VEO disease. The child’s affected father (II-1) had the
same mutation as was seen in his daughter. The third
family, UC591, had several individuals (I-1, II-1, and III-
1) with aneurysms, including one (III-1) with both VEO
disease and an aneurysm. There were two additional
individuals in the family (both cousins of III-1) who had
VEO disease but for whomDNA samples were not avail-
able. Although each of these three families had individ-
uals who were severely affected, there were also indi-
viduals with renal cystic disease and a more routine
presentation.
It should be noted that each of these families had been
independently ascertained. Each family resides in a dif-
ferent part of the United States (Texas, California, and
Minnesota) and is unaware of any distant relatives living
in the other communities. Pedigree analysis of at least
four generations of each family revealed no genetic re-
lationship between families. In at least two of the cases
(pedigrees UC138 and UC1334), the PKD1 mutation
was thought to be from an ancestral white-European
source. Both of these families have resided in the United
States since at least the 1800s, but in each case there
may have been an affected ancestor of Irish descent.
Individual I-1 in pedigree 591 had parents of Italian and
Native American descent, but it is not known through
which parent the disease was transmitted. Sincemembers
of family UC591 were informative at a number of in-
tragenic PKD1 polymorphic loci (described in more de-
tail below; see table 4), we sought to use haplotype anal-
ysis to determine whether the mutation in this pedigree
was likely to have had an independent origin. We found
that the PKD1 mutation in all of the families occurred
on the most common haplotype (i.e., wild-type se-
quence) for all intragenic PKD1 polymorphisms (110
tested). Families 591 and 138 had identical alleles for
markers D16S521 (156) and D16S423 (125), but these
were also the most frequent. Therefore, we cannot ex-
clude the possibility that the three families share a com-
mon, distant genetic origin.
PKD1 Missense Variants Not Found in Normals
Three sequence variants in 5′ MR were found to be
absent in 100 normal chromosomes (table 3). Two af-
fected members of pedigree UC1242, a parent and child,
were found to have in exon 17 a GrT transition that
conserved the valine at position 2378. Although the
change is not predicted to affect the protein sequence,
it segregates with the disease haplotype. The new codon,
GTT, is far less commonly used elsewhere in the gene
(19/405 codons for valine) than is the wild-type sequence
of GTG (271/405) and thus, theoretically, could affect
translational efficiency.
Pedigree UC046 had in exon 17 a GrC transversion
that is predicted to result in a nonconservative amino-
acid change (ArgrPro) at position 2392. Although the
residue falls within the REJ domain of PKD1, one of the
PKD1 portions most highly conserved between humans
and Fugu, Arg2392 itself is not conserved between the
species (Sanford et al. 1997). Thus, we are currently
unable to predict the likely consequences of such a
change. Unfortunately, only one member of the pedigree
was available for evaluation, so we could not determine
whether the variant segregated with disease.
Two individuals (parent and child) available fromped-
igree UC519 were heterozygous for a CrT transition
that converts a serine at position 2434 (uncharged polar)
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Figure 5 Pedigree JHU471, with an 11-11 insertion in exon
17 and severe disease. A partial pedigree is shown in panel A.
Members of the family with ADPKD are indicated by blackened
symbols. Affected individuals with VEO disease (hatched symbols)
or cerebral aneurysms (striped symbols) are identified. Panel B
shows the exon 17 SSCA pattern for affected patients. The pro-
band, II-1, has a markedly abnormal pattern. The differences seen
among the other patients are due to a common polymorphism in
exon 17. Panel C shows an aberrant SSCA band (arrow) that was
excised from the gel and sequenced. The sequence of this band
shows an 11-bp insertion, which is indicated by a black line. Figure 6 Three independent pedigrees (UC591, UC1334, and
UC138) with severe ADPKD and an identical 2-bp deletion in exon
15. The three pedigrees shown in the top panel were ascertained
because they had individuals with severe manifestations of ADPKD
(blackened symbols), including aneurysms (striped symbols), and/
or VEO disease (stippled symbols). The middle panel shows an
identical SSCA pattern in exon 15 for members of each pedigree,
as indicated. A normal sample (lane N) was included for compar-
ison. The aberrant bands were excised from the gel for each sample
and were sequenced (data not shown). The PCR product was also
cloned for two individuals (III-1 in pedigree 591, and III-1 in
1334). The bottom panel shows a comparison of the sequences for
normal and mutant clones. The mutant clone contains a deletion
of 2 bp (AG; table 2) that creates loss of an EcoO109I site (data
not shown). The pedigrees in the top panel are not complete.
to phenylalanine (nonpolar). The amino acid in question
is positioned within a highly conserved serine-threo-
nine–rich cluster in the REJ domain, and thus, theoret-
ically, a nonconservative substitution could have path-
ogenic effects.
Intragenic Polymorphisms
A number of polymorphisms were identified and are
listed in table 4. Many of these variants were found to
be present in the homologous loci. This was tested by
examination of the homologous copies present in the
database for the polymorphism in question. If these cop-
ies lacked the variant, DNA of the cell line N23HA and
total genomic DNA of five individuals (lacking the poly-
morphism in PKD1) were then tested for the presence
of the change, by the appropriate restriction digest. On
the basis of these studies, we cannot comment on
whether homologous loci vary, in terms of sequence,
between individuals.
Variants at several of the loci that are physically very
close together in the gene appear to be in tight linkage
disequilibirum. For example, every white individual (12/
12) found to have the exon 20 polymorphism T7919C
also had the exon 21 variant A8124G. The same was
true for the variants in exons 17 and 18. Of note is that
the changes in exons 20 and 21 were found together in
one of the PKD1 homologues in the database, whereas
the changes in exons 17 and 18 were not. It is still un-
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Table 3
Missense and Silent Variants Absent in a Panel of 100 Normal Chromosomes
Pedigree Phenotype Exon
Nucleic-Acid
Change
Amino-Acid
Change
Restriction
Site
UC1242 Aneurysm 17 G7345T Val2378Val Csp6I
UC046 Aneurysm 17 G7386C Arg2392Pro Bsp120I
UC519 Aneurysm 18 C7479T Ser2423Phe DsaI
known whether one of the other homologues whose se-
quence has not yet been determined contains variants in
both exons 17 and 18.
Although most of the variants would not be predicted
to alter the protein sequence, two exceptions were dis-
covered. The first was a TrC transition, in exon 15
(T4406C), that leads to the substitution of an arginine
residue for a tryptophan at position 1399. Several af-
fected individuals were found to be homozygous for this
change, suggesting that it occurs on both affected and
unaffected haplotypes. The residue is predicted to lie in
position 4 of the B strand of the polycystic kid-
ney–disease (PKD) domain 8 (Bycroft et al. 1999). The
substitution does not alter the b-sheet backbone, and
arginine is found in the corresponding position of other
PKD domains. The other variant, a GrC transversion
in exon 19 (G7853C), was noted in a black patient and
is predicted to change a glutamate to glutamine at po-
sition 2548. Although this difference was not seen in
100 white chromosomes, another black patient (from
Belize) was homozygous for the variant. It is unknown
whether this substitution would have any biological con-
sequences, since the Fugu gene has an arginine in the
same position.
Discussion
A number of strategies have been described for mu-
tation detection in the duplicated region of PKD1. Most
of these methods have taken advantage of unique se-
quence in the 3′ region of the PKD1 gene, to design
primers that can be used for amplification of long-range
PCR products. In general, this has permitted analysis of
PKD1 as far 5′ as exon 15, in cDNA, and exon 23, in
genomic DNA. The major limitation has been the length
of the PCR products that can be reliably amplified from
either cDNA or genomic DNA.
A recent study has described by the use of reverse
transcriptase–PCR and PKD1-specific primers to am-
plify the entire PKD1 coding sequence from RNA
(Thongnoppakhun et al. 1999). The method overcomes
many of the obstacles encountered by other investigators
and can readily identify mutations that affect normal
splicing. It has the additional advantage that it can be
performed by use of RNA prepared from blood samples.
The method has a number of important limitations,
however. RNA yields drop rapidly from blood samples
that are not processed immediately after phlebotomy.
This may preclude the use of samples transported from
a distance. In addition, although the use of RNA-based
templates offers the possibility of detection of mutations
that disrupt splicing, one must assume that the mutant
RNAmolecules are stable. It is well recognized that some
mutations result in RNAs that are rapidly degraded. Fi-
nally, one usually seeks to determine the DNA sequence
that is responsible for the observed changes in the RNA
molecule, to confirm the molecular diagnosis. Therefore,
DNA-based techniques are necessary to complement
RNA-based strategies for the precise definition of mu-
tations, and vice versa.
We have identified in exon 15 a PKD1-unique se-
quence where both forward and reverse gene-specific
primers can be placed. We have used these primers to
reliably amplify two templates from genomic DNA that
extend the region of analysis to exon 11. Preliminary
studies suggest that the reverse primer can be less reliably
used with forward primers positioned in more-5′ regions
as well (unpublished observations). We have confirmed
that these PCR products are indeed gene specific. These
reagents should prove useful to investigators who use
either DNA or RNA samples for their mutation analyses.
As noted in the introduction, relatively few PKD1
mutations have been described in the literature, and little
correlation has been observed between the pattern of
mutation and the phenotype. For the current study, we
selected a population of 35 pedigrees with severe man-
ifestations of ADPKD, to evaluate the robustness of our
methods. We concentrated on families with either an-
eurysms or VEO disease, because both features appear
to cluster in families. We reasoned that the familial clus-
tering suggested a possible correlation between the ge-
notype and phenotype in these individuals. In 10 of the
pedigrees, we identified eight definitive mutations, and
all were predicted to result in severely truncated proteins
lacking the intracellular C-terminus, the transmem-
brane-spanning segments, and the REJ domain (if it is
assumed that any of them are translated). Although it
is tempting to speculate that this group of severely af-
fected patients has more-severe mutations, the data do
not yet support this conclusion. The surveyed region
contained ∼5.3 kb, or 38%, of the coding sequence,
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Table 4
Polymorphisms Identified in Exons 11–21
Exon
Nucleic-
Acid
Change Amino Acid
Restriction
Site
Status in
Homologuesa Comment
11 G2911A Pro900Pro Sty I  Segregates with C2941T
11 C2941T Asp910Asp Fok I  Segregates with G2911A
13 T3274C Gly1021Gly EcoO109I 
15 A4876C Ala1555Ala TspRI 
15 G4885A Thr1558Thr XcmI 
15 T4406C Trp1399Arg NciI 
15 C5383T Thr1724Thr HaeIII 
17 T7376C Leu2389Leu Mva II  Segregates with C7652T
18 C7652T Leu2472Leu NsiI  Segregates with T7376C
19 G7853C Glu2548Gln TaqI 
20 T7919C Leu2570Leu Bsa I  Segregates with A8124G
21 A8124G His2638Arg Hha I  Segregates with T7919C
a A minus sign () denotes absence, and a plus sign () denotes presence.
which is consistent with our detection rate (∼29%) in
the region.
There was one surprising result, however, that does
suggest a potential correlation between the severe phe-
notype and genotype. We have identified three separate
pedigrees (∼9% of the total evaluated) that have an iden-
tical mutation (5224del2) in exon 15 of PKD1. Al-
though we cannot exclude the possibility of a distant
common genetic origin, it is important to emphasize that
the families were prospectively selected for evaluation
solely on the basis of their phenotype. Other groups of
investigators failed to detect this mutation in either 135
affected individuals of European ancestry, by use of the
protein-truncation test (Roelfsma et al. 1997), or 24 un-
related individuals screened by direct sequence analysis
(Thomas et al. 1999). These observations suggest that
the 5224del2 mutation is not a common cause of PKD
in populations of European ancestry. Thus, the likeli-
hood that we would have randomly discovered three
families sharing this uncommon mutation is low (P !
; Fisher’s t test).0.008
Further evidence suggesting a possible relationship be-
tween the genotype and phenotype was recently pre-
sented by Hateboer et al. (1999). These investigators
compared the clinical profiles of 10 large Welsh families,
each of which had PKD1-linked disease with a unique
disease-associated haplotype. Interfamilial differences
were observed in a number of clinical parameters, in-
cluding renal survival. The authors concluded that phe-
notypic differences exist between families and that these
are most likely due to the nature of the underling PKD1
mutation.
Although both sets of observations are provocative,
there is ample evidence that refutes a straightforward
correlation between a particular genotype and a more
severe phenotype; for example, mutations in diverse seg-
ments of PKD1 have been associated with more severe
clinical presentations (Peral et al. 1996; Roelfsma et al.
1997). Furthermore, one might expect that affected in-
dividuals within a family would have similar disease se-
verity. Although two of the three families described
above had more than one severely affected member, all
three families also had members with a more classic clin-
ical presentation. A particularly striking example of dis-
cordant phenotypes has been described by Peral et al.
(1996). One of a pair of DZ twins presented with VEO
and a stable nonsense mutation near the 3′ end of the
gene (Tyr3818Stop), whereas the other twin had the mu-
tation but no evidence of cysts, consistent with an adult-
onset disease course.
There are several ways to reconcile the familial clus-
tering of severe manifestations with the contradictory
observations enumerated above. First, several studies
have suggested that the rate at which somatic mutations
accumulate is likely to be one of the major factors that
determine disease severity (Qian et al. 1996; Brasier and
Henske 1997; Watnick et al. 1998b; Koptides et al.
1999). It is possible that certain mutant haplotypes may
influence the rate at which second hits occur, possibly
by promoting mitotic recombination between normal
and mutant alleles (gene conversion). It is also conceiv-
able that the rate of “second hits” may be further influ-
enced by characteristics of the “normal” allele that have
yet to be defined. This could contribute to the phenotypic
differences that are commonly observed between family
members with the same germline mutation. Last, certain
mutations (regardless of their location) may result in
mutant gene products with distinct biological properties
that may, for example, predispose to aneurysm forma-
tion. What seems clear from these considerations is that
the factors involved in determination of the familial clus-
tering of certain severe manifestations of ADPKD are
likely to be complex. Further directed study of mutant
(and “normal”) alleles identified in these families is war-
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ranted and may help to define the basis for more-severe
phenotypes.
In this report, we also have described 10 novel intra-
genic polymorphisms that have several noteworthy fea-
tures. A number of them (table 4) could be demonstrated
to be present in the homologous loci, supporting pre-
vious data that these homologues may serve as a res-
ervoir for sequence variants via gene-conversion events
(Watnick et al. 1998a). The observation that several sets
of alleles appear to be in tight linkage disequilibrium
suggests that each group of changes could have been
introduced into the PKD1 gene as the result of a single
ancient gene-conversion event. Not all of the polymor-
phisms, however, were found to be present in the homo-
logues; for example, two changes (G2911A and
C2941T) that were physically and genetically linked in
exon 11 could not be shown to be present in either
N23HA or the blood DNA of five additional individuals.
It is still possible, however, that these changes arose as
the result of a gene-conversion event, since the sequence
of the homologous loci may not be uniform between
individuals. The existence of gene-conversion events
makes it critical that rigorously tested, locus-specific re-
agents be used for mutation detection.
Although truncating mutations of PKD1 are generally
accepted to be pathogenic, our results highlight the dif-
ficulties in the analysis of amino-acid substitutions in
this protein. One black individual, for example, had in
exon 19 a nonconservative amino-acid change that was
not found in ∼80 whites. It was excluded as a pathogenic
change, since another individual (also black) was ho-
mozygous for the same variant. Not surprisingly, there-
fore, with respect to the normal PKD1 sequence, there
are likely to be interracial and interethnic differences that
will need to be verified by use of ethnically matched
control populations.
Two additional nonconservative amino-acid changes,
absent from a control population, were also identified.
Even though one of these changes segregated with the
affected haplotype, it is difficult to conclude that this
isolated change is pathogenic. One interesting hypothesis
is that in some cases, rather than there being a single
pathogenic mutation, the combined effect of a number
of missense substitutions results in a hypomorphic allele.
As more understanding is gained with respect to the
biology of PKD1, it should be possible to examine this
hypothesis by the testing of missense variants in func-
tional assays. This type of analysis may also give im-
portant clues regarding critical areas of the protein
structure.
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